Anthropic has established a physical biology facility in the San Francisco Bay Area, moving its artificial intelligence efforts in life sciences from computational models to hands-on experimentation.

Two people familiar with the plans told Reuters that the company built a wet lab. Eric Kauderer-Abrams, Anthropic’s life sciences leader, confirmed the facility. The company aims to test AI-generated ideas through real-world experiments, particularly for treatments targeting rare diseases.

Operational Strategy

Anthropic is combining internal laboratory work with external collaborations, mirroring the operational model of many biotechnology companies. A spokesperson clarified that the facility is not exclusively dedicated to drug discovery and declined to provide further details on its scope.

The company is also exploring AI-driven laboratory automation. Claude models are being developed to operate automated lab systems, with robots executing experiments while humans oversee safety protocols. Kauderer-Abrams described this as the "very early innings" of using AI to automate lab execution.

Market Position and Partnerships

Anthropic does not intend to compete directly with pharmaceutical or biotech companies focused on bringing drugs to market. The company is not conducting clinical trials but plans to focus on preclinical programs in areas lacking sufficient commercial incentive for traditional drugmakers.

Simultaneously, Anthropic provides AI services to established drugmakers including Roche’s Genentech, Bristol Myers Squibb, and Novo Nordisk. In August, the company introduced the Model Hardware Standard to facilitate interaction between AI systems and laboratory equipment.

What the Numbers Show

Hiring data indicates a shift toward operational scale. Job listings seek expertise in protein and nucleic acid characterization and leadership in procurement and operations. One listing explicitly stated the goal to "speed up progress in the life sciences by an order of magnitude," signaling an aggressive timeline for integrating AI into physical biological workflows.

Anthropic and Accenture (NYSE: ACN) have announced a partnership to conduct independent safety evaluations of Anthropic's frontier artificial intelligence models. Both companies have committed to investing at least $1 billion each in the initiative over the next five years.

Partnership Structure and Scope

The collaboration will be led by Faculty, Accenture's AI business unit. The scope of work includes evaluating and red-teaming Anthropic's models, conducting alignment assessments, and testing model safeguards.

The arrangement is structured as an "embedded evaluation." This model allows evaluators to work inside the AI company with access comparable to that of an employee. Evaluators will observe models during training, monitor decisions governing model building and deployment, and interact directly with staff. Anthropic stated it will fund Accenture's work directly under this arrangement.

Accenture will leverage its decades of investment in responsible AI, deep technical and safety expertise through its acquisition of Faculty, one of the world's leading applied AI companies. Faculty is a recognized expert in testing and evaluating models for some of the world’s leading AI labs and has extensive experience building complex AI systems that are safe and ethical by design. Faculty's work spans government, defense, healthcare and infrastructure, including development of the UK National Health Service's Early Warning System during the COVID-19 pandemic.

Leadership Commentary

Julie Sweet, chair and CEO of Accenture, stated that Accenture is bringing together a dedicated team with deep AI, security and industry expertise to work alongside Anthropic. She noted that safety requires both deep technical expertise and a clear understanding of how AI is used in the real world. Sweet described embedded evaluation as an emerging area and expressed anticipation for partnering with Anthropic to help accelerate the development of embedded evaluators, which she sees as an important part of the safety landscape going forward.

Dr. Marc Warner, chief technology officer of Accenture and CEO of Faculty, added that Faculty was founded on the belief that AI should be safe by design, not safe by accident. He stated that joining forces with Anthropic as embedded evaluators is exactly the kind of work Faculty was built to do and that as part of Accenture, they have the platform to do it at a scale that can genuinely move the industry.

Industry Context and Future Plans

Anthropic described embedded evaluation as distinct from existing external evaluation practices. The company noted there are currently no established standards for what information embedded evaluators should access or how findings should be reported. Anthropic said it views long-term funding for such evaluations as ideally coming from pooled or government sources.

The partnership is non-exclusive. Anthropic plans to announce additional evaluators in the coming weeks, and Accenture may work with other AI developers in similar capacities. Anthropic is also in discussions with METR and other nonprofit evaluators to pilot elements of embedded evaluation using separate funding.

Anthropic stated that the use of independent evaluators does not shift responsibility for model safety away from the company. The announcement was framed as an early step toward a broader commitment to embed evaluators within Anthropic, as outlined previously by the company's chief executive.